MR imaging-guided prostate biopsy: technical features and preliminary results.
Repeatedly negative prostate biopsies in individuals with elevated prostate-specific antigen (PSA) levels can be frustrating for both the patient and the urologist. This study was performed to investigate if magnetic resonance imaging (MRI)-guided transrectal biopsy (MRGB) increases diagnostic performance in individuals with suspected prostate cancer (PCa). Twenty-three consecutive men with a total PSA >4 ng/mL, PSA density >0.15, PSA velocity >0.75 ng/mL/year and suspicious MRI findings were included (average age 64 years; age range 53-75 years; total PSA levels ranging from 4.7 to 54 ng/mL; median 9 ng/mL). MRGB was performed with a closed unit at 1.5 Tesla, an MRI compatible biopsy device, a needle guide, and a titanium double-shoot biopsy gun. At prebiopsy MRI, in the 23 patients, a total of 26 suspicious areas to which the MRGB should be directed were found, 23 of them in the peripheral zone and three in the transitional zone. The needle guide was depicted and could be positioned with MRI guidance in all 23 patients. The duration of the procedure ranged from 35 to 55 min (mean 40 min). MRGB was well tolerated by all patients, and no major complications were observed. The detection rate for the diagnosis of PCa was 80, and 90 % of detected PCa were of intermediate aggressiveness. MRGB has the potential to improve cancer detection rates in men with suspected PCa to deliver the relevant treatment as soon as possible.